Medical Pharmacology: Cancer Chemotherapy Drugs: Topoisomerase Inhibitors

Medical Pharmacology: Cancer Chemotherapy Topoisomerase Inhibitors Practice Questions

Etoposide (Toposar):
1. Derivative of podophyllotoxin
2. IV and oral formulations have been FDA approved for clinical use (USA)
3. Both
4. Neither
Dose reduction of etoposide:
1. In patients with liver dysfunction
2. In patients with renal dysfunction
3. Both
4. Neither
Primary etoposide mechanism of action:
1. Inhibition of tyrosine transport
2. Protein kinase inhibition
3. Topoisomerase II inhibitor
4. DNA alkylation
Clinical use/uses of etoposide:
1. Small cell and non-small cell lung cancer
2. Hodgkin's and non-Hodgkin's lymphoma
3. Both
4. Neither
Etoposide may be used in treating gastric cancer.
1. True
2. False
Etoposide acute toxicity/toxicities:
1. Nausea and vomiting
2. Alopecia
3. Myelosuppression
4. A & B
5. A, B & C
Camptothecins are inhibitors of topoisomerase I enzyme activity.
1. True
2. False
Concerning irinotecan adverse effect(s):
1. Diarrhea occurring within 24 hours
2. Diarrhea occurring 2-10 days following administration
3. Both
4. Neither
Irinotecan is approved as first-line treatment in patients with metastatic colorectal cancer when administered along with 5-fluorouracil (5-FU) and leukovorin.
1. True
2. False
Topotecan dosage should be adjusted in patients demonstrating renal impairment..
1. True
2. False